Research Corporation Technologies, Inc.
Research Corporation Technologies, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Research Corporation Technologies, Inc..
Research Corporation Technologies, Inc. is a company.
Key people at Research Corporation Technologies, Inc..
Research Corporation Technologies, Inc. (RCT) is a Tucson, Arizona-based technology investment and management company founded in 1987, specializing in early-stage funding, development, and licensing for biomedical innovations originating from universities and research institutions worldwide.[1][2][5] With assets under management reported between $200 million and over $500 million, RCT's mission centers on commercializing academic technologies into therapeutics, diagnostics, medical devices, and life science tools through venture capital, partnerships, and nonexclusive licensing programs.[1][2][4][5] Its investment philosophy emphasizes technologies with strong competitive edges in biomedicine, supported by mentorship via initiatives like MedTech Innovator, fostering impact in the startup ecosystem by bridging research to market-ready products.[1][5]
RCT targets key sectors including biotechnology, medical devices, therapeutics, genomics, pharmaceuticals, and enabling tools like protein expression platforms, with a track record in blockbuster successes such as cisplatin, carboplatin, PSA tests, and Vimpat.[3][5] Portfolio examples include Biolog (microbial profiling), DisperSol Technologies (pharmaceuticals with $10M+ financing), seqWell (genomics with $9M Series B), and recent investments like Pheon Therapeutics ($120M Series B).[1][4]
RCT traces its roots to a vision chartered in 1912 by Frederick Gardner Cottrell, a university professor and inventor who advocated transferring academic innovations to commercial use; the company formalized in 1987 as a dedicated technology investment firm.[1][4] Initially building on Research Corporation's legacy in patent management and tech transfer, RCT evolved to focus on biomedical ventures, establishing affiliates like Cambridge Research Biolventures in the UK and alliances with Start-Up Australia for global reach.[2][4]
Key leaders include CEO Paul M. Grand (also MedTech Innovator CEO), President of Biotechnologies Shaun A. Kirkpatrick, and President of Medical Devices & CFO Christopher P. Martin, who guide its operations from Tucson with coastal staff support.[1] Pivotal early contributions include commercializing landmark biomedical products, solidifying RCT's role in academic-to-industry translation.[3]
RCT rides the wave of academic DeepTech commercialization in biomedicine, capitalizing on surging demand for university-sourced therapeutics and diagnostics amid aging populations and post-pandemic R&D acceleration.[1][5] Timing aligns with increased institutional pressure for tech transfer, where RCT's model efficiently scales lab breakthroughs into market products, countering funding gaps in early-stage biotech.[2][4]
Market forces like rising VC interest in genomics, devices, and enabling tools (e.g., spray drying acquisitions) favor RCT, as does policy emphasis on innovation pipelines.[1][5] It influences the ecosystem by mentoring via MedTech Innovator, licensing accessible tools globally, and proving ROI through exits/acquisitions, thus amplifying university impact on healthcare advancements.[1][3]
RCT is poised to expand in high-growth biomedical niches like next-gen therapeutics and manufacturing tools, leveraging its $500M+ assets for larger Series B plays amid biotech rebound.[1][4][5] Trends such as AI-driven discovery, precision medicine, and global supply chain resilience will shape its trajectory, potentially through more acquisitions (e.g., recent Particle Dynamics move) and international expansions.[5]
Its influence may evolve toward deeper enabling-tech dominance, sustaining the Cottrell legacy by fueling the next wave of academic blockbusters in an era of complex, capital-intensive biomed innovation—reinforcing RCT's foundational role in bridging research to real-world health solutions.[3][4]
Key people at Research Corporation Technologies, Inc..
